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~bstract The human colon contains many open-type ndocrine 
cells which express the preproglucagon gene and possess gin- 
cagon-like peptide-1 (GLP-1) immunoreactivity, but the molecu- 
lar form of the peptide is unknown. Acid ethanol extracts of 
human colon (n = 4) were subjected to gel filtration and succes- 
sive purification by high-pressure liquid chromatography, moni- 
tored by specific RIAs. A single GLP-l-immunoreactive peak 
was isolated and identified as GLP-I (7-36)amide by amino acid 
sequence analysis and mass spectrometry. We conclude that pro- 
gincagon is processed in the large intestine in the same manner 
as in the small intestine, and results in the formation of fully 
processed biologically active GLP-1. 
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I. Introduction 
The preproglucagon gene is expressed in both the pancreatic 
A-cells and the intestinal L-cells [1], but the primary transla- 
tional product, proglucagon (PG) undergoes differential 
posttranslational processing [2,3]. In the pancreas, the major 
products are glicentin-related pancreatic polypeptide (GRPP; 
corresponding toPG 1-30), glucagon (PG 33-61) and the major 
proglucagon fragment (PG 72-158) [4], whilst in the small intes- 
tine, glicentin (PG 1-69), GRPP, oxyntomodulin (PG 33-69), 
glucagon-like peptide-1 (GLP-1; PG 78-107amide) and GLP-2 
(PG 126-158) are the main molecular forms [reviewed in 5]. 
Many L-cells are also found in the large intestine, where the 
preproglucagon gene is also known to be expressed [1,6] in 
enteroglucagon producing cells [7,8]. GLP-1 and GLP-2 im- 
munostaining is co-localised with glicentin/enteroglucagon 
staining in open-type ndocrine cells in the ileum of all mam- 
mals studied so far [6,9-11], and GLP-1 immunostaining has 
been shown in both the colon [12] and the rectum [10]. How- 
ever, although the presence of a GLP-1-immunoreactive moiety 
has been demonstrated in the large intestine, it is not known 
how proglucagon is processed in the large intestine, or whether 
true biologically active GLP-I  (7-36)amide is formed. 
This study aimed to isolate and purify the GLP-I- im- 
munoreactive material in the human colon and to ascertain its 
molecular nature. 
2. Materials and methods 
2.1. Tissue 
Human colonic tissue (whole wall thickness; n = 4) was obtained 
during surgery on the gastrointestinal tract after approval of the local 
ethical committee. The tissue was immediately frozen and subsequently 
extracted with acid ethanol as previously described [method for neutral 
and basic peptides; 13]. Briefly, the frozen tissue was homogenised in 
4 vols. of acid ethanol, stirred overnight at 4°C and centrifuged. 5 vols. 
of cold diethyl ether were added to the supernatant, and the aqueous 
phase was isolated at -50°C. The precipitate was dissolved in distilled 
water. 
2.2. Purification 
The tissue extracts were subjected to gel permeation chromatography 
on Sephadex G50 Fine grade columns (Pharmacia, Uppsala, Sweden) 
equilibrated and eluted with 0.5 M acetic acid (16 x 1000 mm at a flow 
rate of 0.3 ml/min or 50 x 1000 mm at 1 ml/min). Trace amounts of 
[~2sI]-labelled albumin and '-2NaCI were added to all samples for internal 
calibration. Fractions were collected and assayed using the RIAs de- 
scribed below. 
Fractions containing GLP-1 immunoreactivity were pooled, lyophil- 
ised and redissolved in 0.1% trifluoroacetic acid (TFA; Rathburn, 
Walkerburn, UK). These were subjected to analytical reverse-phase 
high-pressure liquid chromatography (HPLC) using LKB equipment 
with an MN cartridge system (Macherey-Nagel, Dtiren, Germany) fit- 
ted with a 4 x 100-mm Nucleosi1300-7 /am C6H5 column equipped with 
a precolumn. The column was eluted with step-wise linear gradients of 
acetonitrile (AcN; Rathburn) in 0.1% TFA (0% AcN for 12 min fol- 
lowed by 0-75% over 45 min; 1 ml/min), and fractions (1 ml) were 
assayed as described below. The immunoreactive p ak was further 
purified using a 4 x 100-mm Nucleosil 120-5/am Cs column (0% AcN 
for 8 rain followed by 0-30% over 5 min, 30-35% over 15 min and 
35 75% over 3 min; 2 ml/min; 500/11 fraction size), a Nucleosil C6H5 
column as above (0% for 3 min, followed by 0-31% over 5 rain, 31-37% 
over 20 min and 37-75% over 3 min; 1.5 ml/min; 500/al fraction size) 
and a C8 column as before. The final purification was on a Hewlett 
Packard HP 1090 system using a 2.1 x 150-mm Vydac C~8 column 
eluted at a flow rate of 200/al/min (10 25% AcN over 5 rain followed 
by 25-36% over 55 rain and 36-90% over 1 min). The peak eluting at 
~33% AcN was collected for mass and sequence analysis. 
2.3. Amino acid sequence analysis 
Aliquots of the purified peptide were sequenced using an automatic 
protein sequencer (Procise HT; Applied Biosystems, Foster City, CA) 
with on-line HPLC detection of the phenylthiohydatoin derivatives. All 
chemicals and solvents were of sequence or HPLC grade (Applied 
Biosystems). 
2.4. Mass spectrometry 
The molecular mass of the purified peptide was determined by ma- 
trix-assisted laser desorption ionization mass spectrometry using a 
Biflex instrument (Bruker, Bremen, Germany). A 0.25-/al aliquot of the 
purified peptide was spotted on a layer of ~-cyano-4 hydroxy cinnamic 
acid, which was obtained by allowing 0.25/al of a saturated solution of 
this matrix in AcN to dry. The samples were analysed in the linear mode 
with external calibration using dynorphin A and bovine insulin. The 
accuracy obtained with this method is > 0.1%. 
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2.5. RIAs 
Fractions were assayed using three antisera raised against GLP-1. 
Antiserum 2135 [11,14] is side-viewing and detects all molecules with 
the central sequence of GLP-1 (7 36)amide, recognising both N- and 
C-terminally truncated or extended peptides. Antiserum 91022 [4] is 
directed towards the N-terminal sequence of GLP-1 (7-36)amide, and 
cross-reacts fully with N-terminally extended or C-terminally truncated 
fragments but < 0.2% with N-terminally truncated peptides. Antiserum 
89390 [15,16] has an absolute requirement for the intact amidated 
C-terminus of GLP-1 (7 36)amide, and cross-reacts <0.01% with C- 
terminally truncated or extended forms. For all assays, standard and 
[]251]-labelled tracer were GLP-1 (7 36)amide, and separation of anti- 
body-bound from free peptide was achieved using plasma-coated char- 
coal [11,15]. 
Fractions were also assayed using two antisera raised against glu- 
cagon. Antiserum 4304 [17] measures all peptides containing the 6-15 
sequence of glucagon, including glucagon itself, and the entero- 
glucagons, including licentin and oxyntomodulin. Antiserum 4305 [17] 
is specific for the C-terminus of glucagon, and only detects peptides 
with a fully processed C-terminus, and does not cross-react with gli- 
centin or oxyntomodulin. 
3. Results 
The colonic extracts contained similar amounts of im- 
munoreactive GLP-1 (wet weight; mean + S.E.M.; n = 4) corre- 
sponding to 36 + 23 pmol/g (side-viewing RIA), 24 + 15 pmol/g 
(N-terminal RIA) and 36 + 25 pmol/g (C-terminal RIA). 
Analysis of the tissue extracts by gel filtration revealed a 
single GLP-l- immunoreactive p ak at Kj 0.56 measured with 
all three GLP-1 antisera (Fig. 1). This corresponds to the elu- 
tion position of synthetic GLP-1 (1-36)amide and GLP-1 (7- 
36)amide which, as previously shown, are difficult to distin- 
guish by gel filtration [11]. 
Measurement of the same fractions with the side-viewing 
glucagon antiserum (4304) gave two peaks eluting in the posi- 
tions of glicentin and oxyntomodulin ( ot shown), as in previ- 
ous investigations [11]. No immunoreactivity was detected with 
the C-terminal assay for glucagon. 
Analysis of the GLP-1-immunoreactive material from the gel 
filtration by successive HPLC separations showed that the pep- 
tide eluted as a single immunoreactive p ak, detected equally 
by all three GLP-1 assays (Fig. 2). This peak eluted at the 
position of GLP- 1 (7-36)amide, determined by calibration with 
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Fig. 1. Gel filtration of an extract of human colon analysed using 
C-terminal amide-specific (89390; o-o), N-terminally directed (91022; 
~-A) and processing-independent (2135; e-e) RIAs for GLP-1. The 
concentration is plotted against he coefficient of distribution (Ka). 
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Fig. 2. HPLC analysis of the GLP-l-immunoreactive material eluting 
from the gel filtration columns howing the first separation on a Nucle- 
osil C6Hs column (A) and the final purification on a Vydac C~8 column 
(B). The optical density (milli absorbance units) is plotted against reten- 
tion time, and fractions were assayed using C-terminal amide-specific 
(89390), N-terminally directed (91022) and processing-independent 
(2135) RIAs for GLP-1. 
the synthetic standard after chromatography of the colonic 
material was complete. The final purification on a Vydac C~8 
column yielded an apparently pure peptide which was subjected 
to mass and sequence analysis. 
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Fig. 3. Mass spectrum of the immunoreactive material eluting from the 
final HPLC purification on a Vydac C~s column. ~0.1 pmol was analysed 
by laser desorption ionization mass spectrometry. The values given 
above the peaks indicate the molecular masses of the molecular ions 
(MH+). 
Protein sequence analysis enabled the entire sequence to be 
obtained. This was identical with GLP-I (7-36), with the pres- 
ence of the C-terminal amide being unequivocally confirmed by 
positive binding in the C-terminal RIA which has an absolute 
requirement for an amidated arginine at position 36 [16]. 
The molecular mass was determined to be 3298.0 compared 
with a theoretical mass of 3297.7 for GLP-1 (7-36)amide 
(Fig. 3). 
4. Discussion 
The ileal L cells express the preproglucagon gene, and it is 
well-established that posttranslational processing results in the 
parallel secretion of GLP-1 (7-36)amide with the intestinal en- 
teroglucagon, glicentin [reviewed in 5]. Similar L-cells are found 
in the large intestine [7,8] and preproglucagon gene expression 
has been demonstrated in the colon [1,6]. These observations, 
together with the demonstration of GLP-l-immunoreactive 
staining co-localising with glicentin in the ileum [6,9,11], colon 
[12] and rectum [10], and the presence of GLP-1 immunoreac- 
tivity in tissue extracts of large and small intestine [6] led to the 
assumption that processing of proglucagon i  these tissues is 
similar, even though the molecular nature of the GLP-1 im- 
munoreactivity was not identified. In a later study, Mojsov et 
al. [18] showed that the majority of GLP-1 immunoreactivity 
in the rat large and small intestine co-eluted on HPLC with 
synthetic GLP-I (7-36)amide, although a small proportion 
eluted in the position of non-amidated, glycine-extended GLP- 
1 (7-37). The present study has shown that fully processed 
GLP-I (7 36)amide is found in the human colon, in concentra- 
tions which are similar to those reported for the human small 
intestine [11]. It should be emphasised that with the employed 
techniques for extraction and chromatographic analysis, alter- 
native processing products could not have escaped etection, 
since this methodology has been demonstrated to extract quan- 
titatively all molecular forms of proglucagon processing 
[4,14,19,20], and the entire gel filtration of the extract was 
analysed without discarding side fractions. Mass determination 
revealed a component with a mass of 3356.6, which is close to 
that of GLP-I (7-37). This probably represents a minor con- 
taminant, since the HPLC methodology is capable of separat- 
ing GLP-I (7-36)amide from GLP-1 (7 37), and a glycine ex- 
tension was not detected by sequence analysis. An N-terminally 
truncated metabolite, GLP-I (9-36)amide, has recently been 
identified in human plasma [21]. It is noteworthy that this 
metabolite was not identified in the colonic tissue extracts, 
indicating that this metabolism occurs outside the tissue, once 
the peptide has been released. 
GLP-1 is released from the small intestine in response to the 
same physiological stimuli which are known to cause release of 
glicentin (reviewed by Orskov [3]). Whilst the release of GLP-1 
by the large intestine has not been demonstrated, this is likely 
to be the case, given that enteroglucagon a d GLP-1 are co- 
secreted in the ileum [5]. Thus, instillation of glucose [22,23] or 
fermentable fibre [24] into the colon which stimulate the release 
of enteroglucagon is likely to also cause GLP-1 secretion. GLP- 
1 secretion is, therefore, likely to be stimulated by the presence 
of undigested nutrients in the colon, which occurs in certain 
pathological conditions in which abnormal amounts of unab- 
sorbed nutrients reach the distal intestine and are associated 
with elevated concentrations of enteroglucagons [5]. A co-se- 
cretion of GLP-1, by virtue of its effects on gastric emptying 
[25] would be beneficial by delaying the supply of further nutri- 
ents. 
In conclusion, this study has shown that the human colon 
produces fully processed biologically active GLP-1 in concen- 
trations which are high enough to have a physiological role. 
Further studies are required to assess the importance of the 
colon as a source of GLP-I. 
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